TTC1 Antibody

What is TTC1 and why is it important in research?

TTC1, also known as Tetratricopeptide repeat protein 1 or TPR1, is a protein containing tetratricopeptide repeat domains that facilitate protein-protein interactions. The full-length human TTC1 protein consists of 292 amino acids with a calculated molecular weight of 33.5 kDa, though it typically appears at approximately 34 kDa in experimental conditions . TTC1 is important in research due to its role in cellular signaling pathways and protein complex formation, making it a valuable target for studying diverse biological processes.

What species reactivity is available for TTC1 antibodies?

TTC1 antibodies are available with reactivity to multiple species, primarily:

• Human TTC1 antibodies (most common)

• Mouse TTC1 antibodies

• Rat TTC1 antibodies

When selecting an antibody, verify cross-reactivity with your experimental model. For example, antibody 11676-1-AP has been validated to show reactivity with human, mouse, and rat samples, making it versatile for comparative studies across these species .

What applications are TTC1 antibodies validated for?

TTC1 antibodies have been validated for numerous experimental applications:

It's important to note that each antibody should be validated in your specific experimental system as performance can vary depending on sample type and preparation method .

How should I select the appropriate TTC1 antibody for my experiment?

When selecting a TTC1 antibody, consider the following factors:

• Experimental application: Ensure the antibody is validated for your specific application (WB, IHC, IF, etc.)

• Species reactivity: Confirm reactivity with your experimental model

• Clonality: Choose between:

  • Polyclonal antibodies (e.g., rabbit polyclonal) - offer broader epitope recognition

  • Monoclonal antibodies (e.g., mouse monoclonal 4E3) - provide consistent specificity

• Validated cell/tissue types: Verify performance in systems similar to yours. For example, TTC1 antibody 11676-1-AP has been validated in several cell lines including HEK-293, HepG2, Jurkat, and HeLa cells for Western blot applications, and in human colon cancer tissue for IHC applications .

Always review validation data, including images and publications citing the antibody, before making your selection.

What are the optimal storage conditions for TTC1 antibodies?

For most TTC1 antibodies, optimal storage conditions include:

• Temperature: Store at -20°C

• Buffer composition: Typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Stability: Generally stable for one year after shipment when stored properly

• Aliquoting: For most -20°C storage, aliquoting is unnecessary, though it may be recommended for frequently used antibodies to prevent freeze-thaw cycles

Some antibody preparations may include stabilizers such as 0.1% BSA for small volume formats (e.g., 20μl sizes) . Always consult the product-specific datasheet for exact storage recommendations.

What controls should I include when working with TTC1 antibodies?

Robust experimental design with TTC1 antibodies should include:

• Positive controls: Validated cell lines known to express TTC1, such as:

  • HEK-293 cells

  • HepG2 cells

  • Jurkat cells

  • HeLa cells

• Negative controls:

  • Primary antibody omission

  • Isotype control (matching the host species and isotype of your TTC1 antibody)

  • TTC1 knockdown/knockout samples (if available)

• Loading controls: For Western blot applications, include housekeeping proteins appropriate for your experimental system

Including these controls helps validate antibody specificity and ensures reliable interpretation of results.

How can I optimize TTC1 antibody performance for immunohistochemistry?

For optimal IHC results with TTC1 antibodies:

• Antigen retrieval:

  • Primary method: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Antibody dilution: Begin with the recommended range (1:20-1:200 for antibody 11676-1-AP) and titrate as needed

• Incubation conditions:

  • Temperature: 4°C

  • Duration: Overnight incubation often yields optimal signal-to-noise ratio

  • Environment: Humid chamber to prevent tissue drying

• Detection system:

  • Select a detection system compatible with your host species (e.g., rabbit IgG detection system for rabbit polyclonal antibodies)

  • Consider signal amplification methods for low-abundance targets

• Counterstaining: Hematoxylin provides good nuclear contrast without masking TTC1 signal

When troubleshooting, systematically adjust individual parameters while maintaining others constant to identify optimal conditions for your specific tissue samples.

What approaches can be used to study TTC1 protein interactions?

TTC1 contains tetratricopeptide repeat domains that mediate protein-protein interactions. To study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Use TTC1 antibodies validated for IP applications

  • Consider both forward (IP with anti-TTC1) and reverse (IP with antibody to suspected interacting protein) approaches

  • Optimize lysis buffer conditions to preserve protein complexes

• Proximity ligation assay (PLA):

  • Utilize validated TTC1 antibodies from different host species (e.g., rabbit and mouse)

  • Provides in situ detection of protein interactions with spatial resolution

• Pull-down assays:

  • Use recombinant TTC1 protein (such as ab130015) as bait

  • Identify novel interaction partners through mass spectrometry of pulled-down complexes

• CRISPR/Cas9 genetic modification:

  • Design guide RNAs targeting TTC1 (available for mouse models)

  • Create knockout or knock-in cell lines to study functional consequences of TTC1 interactions

These approaches provide complementary insights into TTC1's interactome and functional roles in cellular processes.

How can I address cross-reactivity concerns with TTC1 antibodies?

Cross-reactivity can complicate data interpretation. To address this:

• Validate specificity:

  • Compare multiple antibodies targeting different epitopes of TTC1

  • Use CRISPR/Cas9 knockout controls to confirm signal specificity

  • Consider peptide competition assays to verify epitope-specific binding

• Optimize experimental conditions:

  • Adjust antibody concentration (starting with recommended dilutions, e.g., 1:2000-1:12000 for WB)

  • Modify blocking conditions to reduce non-specific binding

  • Increase washing stringency to remove weakly bound antibody

• Consider antibody format:

  • For challenging applications, compare polyclonal and monoclonal options

  • Monoclonal antibodies (e.g., 4E3 clone) may offer greater specificity in some contexts

• Pre-absorption:

  • Pre-incubate antibody with recombinant TTC1 protein to absorb specific binding

  • Compare pre-absorbed and standard antibody results to identify specific signal

How should I quantify TTC1 expression in Western blot analysis?

For accurate quantification of TTC1 expression by Western blot:

• Sample preparation:

  • Ensure equal protein loading (10-30 μg total protein typically sufficient)

  • Include gradient standards if absolute quantification is required

• Detection considerations:

  • TTC1 appears at approximately 34 kDa (observed) versus 33.5 kDa (calculated)

  • Use appropriate exposure times to avoid signal saturation

• Normalization approaches:

  • Normalize to housekeeping proteins appropriate for your experimental system

  • Consider total protein normalization methods (e.g., Stain-Free technology) when expression of common housekeeping proteins might vary

• Densitometric analysis:

  • Use linear range of detection for quantification

  • Average multiple technical replicates

  • Report relative fold changes rather than absolute values unless standards are included

• Statistical analysis:

  • Apply appropriate statistical tests based on your experimental design

  • Consider biological variation when interpreting results

Following these guidelines ensures more reliable quantitative comparisons of TTC1 expression across experimental conditions.

How can I resolve discrepancies in TTC1 localization between IF and biochemical fractionation?

When facing contradictory results between immunofluorescence (IF) and biochemical fractionation for TTC1 localization:

• Validate antibody specificity in both applications:

  • Ensure the TTC1 antibody is validated for both IF (1:50-1:500 dilution) and WB applications

  • Consider using multiple antibodies targeting different epitopes

• Optimize fixation and permeabilization for IF:

  • Compare paraformaldehyde, methanol, and acetone fixation

  • Adjust permeabilization conditions that might affect epitope accessibility

• Refine fractionation protocols:

  • Verify fractionation efficiency using established markers for each cellular compartment

  • Consider that harsh fractionation buffers might disrupt protein complexes

• Consider biological explanations:

  • TTC1 might shuttle between compartments depending on cellular conditions

  • Post-translational modifications could affect antibody recognition in different contexts

  • Protein interactions might mask epitopes in specific cellular compartments

• Employ complementary approaches:

  • Use GFP-tagged TTC1 constructs for live-cell imaging

  • Consider super-resolution microscopy for more precise localization

Integrating findings from multiple methodological approaches provides a more complete understanding of TTC1's dynamic localization patterns.

What considerations are important when comparing TTC1 expression across different tissues?

When comparing TTC1 expression across different tissues:

• Sample preparation optimization:

  • Adjust extraction protocols for tissue-specific characteristics

  • Consider tissue-specific fixation times for IHC applications

• Antibody validation:

  • Verify TTC1 antibody performance in each tissue type

  • TTC1 antibody 11676-1-AP has been validated in human colon cancer tissue for IHC but may require optimization for other tissues

• Controls and normalization:

  • Include tissue-specific positive and negative controls

  • For quantitative comparisons, normalize to appropriate reference genes verified as stable in the tissues being compared

• Technical considerations:

  • Account for tissue-specific autofluorescence in IF applications

  • Consider antigen retrieval variations (TE buffer pH 9.0 versus citrate buffer pH 6.0) for optimal results in different tissues

• Biological interpretation:

  • Consider tissue-specific post-translational modifications that might affect antibody recognition

  • Interpret expression patterns in the context of tissue-specific function

These methodological considerations help ensure that observed differences in TTC1 expression reflect genuine biological variation rather than technical artifacts.

How can TTC1 recombinant proteins be used to advance research?

Recombinant TTC1 proteins, such as the full-length human TTC1 protein (1-292 amino acids), offer valuable research tools:

• Antibody validation:

  • Use as positive controls in Western blot applications

  • Generate standard curves for quantitative analyses

• Structural studies:

  • High-purity (>85%) recombinant protein is suitable for structural analysis via X-ray crystallography or NMR

  • Investigate specific domains responsible for protein-protein interactions

• In vitro binding assays:

  • Use as bait protein in pull-down assays to identify interaction partners

  • Characterize binding affinities and kinetics using surface plasmon resonance (SPR)

• Functional studies:

  • Investigate effects of exogenous TTC1 on cellular processes

  • Develop activity assays to screen for modulators of TTC1 function

• Antibody development:

  • Generate new antibodies using recombinant TTC1 as immunogen

  • Produce epitope-specific antibodies targeting functional domains

Recombinant TTC1 proteins expressed in systems like Escherichia coli provide consistent, well-characterized research reagents for diverse experimental applications .

What methodological approaches are available for studying post-translational modifications of TTC1?

To investigate post-translational modifications (PTMs) of TTC1:

• Mass spectrometry-based approaches:

  • Immunoprecipitate TTC1 using validated antibodies

  • Analyze by LC-MS/MS to identify PTMs

  • Consider enrichment strategies for specific modifications (e.g., phosphopeptide enrichment)

• Western blot analysis:

  • Use modification-specific antibodies (e.g., anti-phospho, anti-ubiquitin)

  • Perform mobility shift assays (native PAGE, Phos-tag gels)

  • Compare molecular weight with predicted (33.5 kDa) versus observed (34 kDa) sizes

• Site-directed mutagenesis:

  • Mutate potential modification sites in recombinant TTC1

  • Compare functional consequences of mutations

• In vitro modification assays:

  • Use purified recombinant TTC1 protein as substrate

  • Test with known enzymes (kinases, ubiquitin ligases, etc.)

• Inhibitor studies:

  • Treat cells with modification-specific inhibitors

  • Assess effects on TTC1 function, localization, and interaction partners

These methodological approaches provide complementary insights into the regulation of TTC1 through post-translational modifications.

How can CRISPR/Cas9 technology enhance TTC1 research?

CRISPR/Cas9 technology offers powerful approaches for TTC1 research:

• Gene knockout studies:

  • Design guide RNAs specifically targeting the TTC1 gene

  • Generate complete knockout cell lines or animal models

  • Analyze phenotypic consequences to understand TTC1 function

• Knock-in applications:

  • Create endogenously tagged TTC1 (e.g., GFP-TTC1) for live imaging

  • Introduce specific mutations to study structure-function relationships

  • Generate reporter constructs to monitor TTC1 expression

• Validation tools:

  • Generate knockout controls to validate antibody specificity

  • Create isogenic cell lines for controlled comparative studies

• Domain-specific studies:

  • Target specific domains within TTC1 to understand their functional roles

  • Engineer truncated variants to identify essential regions

• High-throughput screening:

  • Combine CRISPR libraries with phenotypic screening

  • Identify genes that interact functionally with TTC1

These CRISPR-based approaches provide precise genetic tools to complement traditional antibody-based methods in TTC1 research .